Olanzapine/fluoxetine

Drug Profile

Olanzapine/fluoxetine

Alternative Names: OFC; Symbyax; ZypZac

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Class Antidepressants; Antipsychotics; Benzodiazepines; Propylamines
  • Mechanism of Action Dopamine D1 receptor antagonists; Dopamine D2 receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Bipolar disorders; Major depressive disorder

Most Recent Events

  • 21 Jun 2012 First Generic equivalent available in USA for Bipolar disorders and Major depressive disorder
  • 31 Mar 2012 Eli Lilly completes a phase III trial in Major depressive disorder in Argentina, India, Mexico, Puerto Rico, Russia, South Africa, Turkey and USA (NCT00958568)
  • 23 Mar 2009 Launched for Depression in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top